Literature DB >> 7809120

Molecular cloning and derived primary structure of cobra venom factor.

D C Fritzinger1, R Bredehorst, C W Vogel.   

Abstract

Cobra venom factor (CVF) is the complement-activating protein in cobra venom. Like C3b, CVF forms with factor B and factor D in human and mammalian serum the bimolecular C3/C5 convertase. This functional similarity of CVF and C3 correlates with many structural similarities, which led to the suggestion that CVF is evolutionally related to C3. We report here the molecular cloning and derived primary structure of CVF. CVF mRNA is > 5924 nucleotides in length. It contains a single open reading frame of 4926 nucleotides, coding for a pre-pro-protein of 1642 amino acids. The deduced amino acid sequence reveals approximately 70% protein similarity to mammalian and human C3 and exceeds 91% in the case of cobra C3. The single-chain pre-pro-CVF consists of a 22-amino acid signal sequence, a 627-amino acid alpha-chain, and a 989-amino acid precursor chain for the CVF gamma- and beta-chains. The processing of pro-CVF involves the removal of 4 arginine residues between the alpha- and precursor chains as well as of the C3a-like and C3d-like domains from the precursor chain, thereby confirming the predicted chain homologies to C3. Pro-CVF contains five potential N-glycosylation sites, of which only three can be expected to be glycosylated in mature CVF. Like C3, pro-CVF contains 27 cysteine residues and a homologous thioester site in the C3d-like region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809120      PMCID: PMC45522          DOI: 10.1073/pnas.91.26.12775

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Human complement component C3: cDNA coding sequence and derived primary structure.

Authors:  M H de Bruijn; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

2.  A 34-amino acid peptide of the third component of complement mediates properdin binding.

Authors:  M E Daoudaki; J D Becherer; J D Lambris
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

3.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

4.  Cobra venom factor: improved method for purification and biochemical characterization.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  J Immunol Methods       Date:  1984-10-12       Impact factor: 2.303

5.  Cobra venom factor: structural homology with the third component of human complement.

Authors:  C W Vogel; C A Smith; H J Müller-Eberhard
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

6.  Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja N. siamensis).

Authors:  G Eggertsen; P Lind; J Sjöquist
Journal:  Mol Immunol       Date:  1981-02       Impact factor: 4.407

7.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

8.  Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).

Authors:  C A Alper; D Balavitch
Journal:  Science       Date:  1976-03-26       Impact factor: 47.728

9.  Immunoreactivity and function of oligosaccharides in cobra venom factor.

Authors:  D C Gowda; E C Petrella; T T Raj; R Bredehorst; C W Vogel
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

10.  Crystal structure analysis and molecular model of human C3a anaphylatoxin.

Authors:  R Huber; H Scholze; E P Pâques; J Deisenhofer
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1980-09
View more
  8 in total

1.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells.

Authors:  Jeong-Hyeon Sohn; Puran S Bora; Hye-Jung Suk; Hector Molina; Henry J Kaplan; Nalini S Bora
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

2.  Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.

Authors:  Bert J C Janssen; Lucio Gomes; Roman I Koning; Dmitri I Svergun; Abraham J Koster; David C Fritzinger; Carl-Wilhelm Vogel; Piet Gros
Journal:  EMBO J       Date:  2009-07-02       Impact factor: 11.598

3.  Multiple forms of complement C3 in trout that differ in binding to complement activators.

Authors:  J O Sunyer; I K Zarkadis; A Sahu; J D Lambris
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

4.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

5.  Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients.

Authors:  James C Oates; Libby W Farrelly; Ann F Hofbauer; Wei Wang; Gary S Gilkeson
Journal:  Arthritis Rheum       Date:  2007-11

6.  The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.

Authors:  Vengadesan Krishnan; Karthe Ponnuraj; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Structure       Date:  2009-04-15       Impact factor: 5.006

7.  Restriction and recruitment-gene duplication and the origin and evolution of snake venom toxins.

Authors:  Adam D Hargreaves; Martin T Swain; Matthew J Hegarty; Darren W Logan; John F Mulley
Journal:  Genome Biol Evol       Date:  2014-08       Impact factor: 3.416

8.  Intracellular sensing of complement C3 activates cell autonomous immunity.

Authors:  Jerry C H Tam; Susanna R Bidgood; William A McEwan; Leo C James
Journal:  Science       Date:  2014-09-04       Impact factor: 47.728

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.